The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.

Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101128966 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5010 (Electronic) Linking ISSN: 15691993 NLM ISO Abbreviation: J Cyst Fibros Subsets: MEDLINE

Original Publication: Amsterdam ; New York : Elsevier, c2002-

Bacterial Infections*/drug therapy ; Bacterial Infections*/etiology ; Cystic Fibrosis*/complications ; Cystic Fibrosis*/drug therapy ; Cystic Fibrosis*/epidemiology ; Hearing Loss*/chemically induced ; Hearing Loss*/diagnosis ; Hearing Loss*/epidemiology ; Hearing Loss*/prevention & control; Amikacin/*adverse effects ; Anti-Bacterial Agents/*adverse effects ; Tobramycin/*adverse effects ; Vancomycin/*adverse effects; Adolescent ; Adult ; Age Factors ; Amikacin/administration & dosage ; Anti-Bacterial Agents/administration & dosage ; Audiometry, Pure-Tone/methods ; Female ; Humans ; Male ; Middle Aged ; Patient Outcome Assessment ; Sex Factors ; Time ; Tobramycin/administration & dosage ; United States/epidemiology ; Vancomycin/administration & dosage

Background: Aminoglycosides (AGs) and glycopeptides are antibiotics essential for treating life-threatening respiratory infections in patients with cystic fibrosis (CF). The goal of this study was to examine the effects of cumulative intravenous (IV)-AG (amikacin and/or tobramycin) and/or glycopeptide (vancomycin) dosing on hearing status in patients with CF.
Methods: Hearing thresholds were measured from 0.25 to 16.0kHz, in 81 participants with CF. Participants were categorized into two groups: normal hearing in both ears (≤25dB HL for all frequency bands) or hearing loss (>25dB HL for any frequency band in either ear). Participants were also characterized into quartiles by their cumulative IV-AG (with or without vancomycin) exposure. Dosing was calculated using two strategies: (i) total number of lifetime doses, and (ii) total number of lifetime doses while accounting for the total doses per day. This was referred to as the "weighted" method.
Results: Participants in the hearing loss group were significantly older than those in the normal-hearing group. After adjusting for gender and age at the time of hearing test, participants in the two highest-quartile exposure groups were almost 5 X more likely to have permanent sensorineural hearing loss than those in the two lowest-quartile exposure groups. There was a small group of CF patients who had normal hearing despite high exposure to IV-antibiotics.
Conclusions: Cumulative IV-antibiotic dosing has a significant negative effect on hearing sensitivity in patients with CF, when controlling for age and gender effects. A trend for increasing odds of hearing loss was associated with increasing cumulative IV-antibiotic dosing.
(Copyright © 2017 European Cystic Fibrosis Society. All rights reserved.)

Eur Rev Med Pharmacol Sci. 2015 Feb;19(4):694-700. (PMID: 25753888)
Ear Hear. 2001 Apr;22(2):161-8. (PMID: 11324845)
Antimicrob Agents Chemother. 1999 Jul;43(7):1549-55. (PMID: 10390201)
Int J Pediatr Otorhinolaryngol. 2010 May;74(5):469-73. (PMID: 20189661)
J Clin Oncol. 2006 Feb 20;24(6):918-24. (PMID: 16484702)
Sci Transl Med. 2015 Jul 29;7(298):298ra118. (PMID: 26223301)
Int J Audiol. 2011 Feb;50(2):112-22. (PMID: 21265638)
Ear Hear. 1990 Dec;11(6):450-4. (PMID: 2073979)
J Assoc Res Otolaryngol. 2014 Aug;15(4):555-70. (PMID: 24845404)
Ann Pharmacother. 2002 Mar;36(3):446-51. (PMID: 11895059)
J Infect Dis. 1992 Jun;165(6):1026-32. (PMID: 1583319)
J Acoust Soc Am. 1986 Feb;79(2):443-6. (PMID: 3950196)
J Otolaryngol. 2007 Oct;36(5):257-63. (PMID: 17963663)
Pediatr Pulmonol. 2009 Apr;44(4):325-9. (PMID: 19330772)
J Antimicrob Chemother. 1978 May;4 Suppl A:73-83. (PMID: 659353)
Eur Arch Otorhinolaryngol. 1994;251(7):375-92. (PMID: 7857625)
Antimicrob Agents Chemother. 1996 Jan;40(1):186-90. (PMID: 8787903)
Antimicrob Agents Chemother. 1991 Mar;35(3):399-405. (PMID: 2039189)
Int J Audiol. 2014 Aug;53(8):531-45. (PMID: 24749665)
Med Toxicol Adverse Drug Exp. 1988 Sep-Oct;3(5):376-86. (PMID: 3057327)
B-ENT. 2014;10(1):53-8. (PMID: 24765829)
Acta Otolaryngol. 2010 Feb;130(2):253-8. (PMID: 19479457)
Laryngoscope. 2005 Apr;115(4):640-4. (PMID: 15805873)
Int J Pediatr Otorhinolaryngol. 2003 Sep;67(9):939-41. (PMID: 12907047)
J Am Acad Audiol. 2016 Jan;27(1):6-12. (PMID: 26809322)
Int J Pediatr Otorhinolaryngol. 2015 Nov;79(11):1915-9. (PMID: 26384832)
Antimicrob Agents Chemother. 2006 Jul;50(7):2293-9. (PMID: 16801404)
Braz J Otorhinolaryngol. 2015 Nov-Dec;81(6):589-97. (PMID: 26480907)
Antimicrob Agents Chemother. 2001 Sep;45(9):2502-9. (PMID: 11502521)
Antimicrob Agents Chemother. 1983 Jun;23(6):897-901. (PMID: 6614894)
Antimicrob Agents Chemother. 1989 Jun;33(6):797-800. (PMID: 2669624)
Acta Otolaryngol. 1988 May-Jun;105(5-6):511-5. (PMID: 3261106)
Infection. 2009 Oct;37(5):424-31. (PMID: 19756418)
J Hosp Infect. 1991 Jun;18 Suppl A:117-29. (PMID: 1679774)
Otolaryngol Head Neck Surg. 2009 Jul;141(1):86-90. (PMID: 19559964)
Scand Audiol. 1991;20(3):205-7. (PMID: 1842291)
Epidemiology. 2007 Sep;18(5):639-48. (PMID: 17700253)
J Infect Dis. 1984 Jan;149(1):23-30. (PMID: 6693788)
Int J Pediatr Otorhinolaryngol. 2003 Apr;67(4):353-7. (PMID: 12663106)
Curr Opin Pulm Med. 2010 Nov;16(6):604-10. (PMID: 20814306)

UL1 TR000128 United States TR NCATS NIH HHS; UL1 TR002369 United States TR NCATS NIH HHS; R01 DC010202 United States DC NIDCD NIH HHS; R01 DC004555 United States DC NIDCD NIH HHS; R01 DC012588 United States DC NIDCD NIH HHS

0 (Anti-Bacterial Agents)
6Q205EH1VU (Vancomycin)
84319SGC3C (Amikacin)
VZ8RRZ51VK (Tobramycin)

Date Created: 20170228 Date Completed: 20180312 Latest Revision: 20190418

20240829

PMC5591745

10.1016/j.jcf.2017.01.006

28238634